Price T Rowe Associates Inc Jounce Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $26,240 - $81,590	41,000 Added 104.23%	80,336 $89,000
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $53,830 - $97,012	19,718 Added 100.51%	39,336 $93,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $125,134 - $342,779	-44,691 Reduced 69.49%	19,618 $59,000
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $325,231 - $462,142	54,115 Added 530.85%	64,309 $437,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $1.36 Million - $1.84 Million	-191,300 Reduced 94.94%	10,194 $85,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $78,805 - $136,502	15,636 Added 8.41%	201,494 $1.5 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $297,626 - $482,173	45,232 Added 32.16%	185,858 $1.26 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $239,789 - $494,188	35,630 Added 33.93%	140,626 $1.44 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $668,824 - $1.08 Million	104,996 New	104,996 $735,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.